Our strategy to abrogate the growth of the U2AF1 mutant cancer cells is to target U2AF1-UHM that binds with U2AF2 to form a dimer recognizing the 3’ splice site in pre-mRNA splicing. The gene discussed is U2AF2; the disease is cancer.